SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy
BiotechTV - News
00:00
Atacicept and IgA Nephropathy Mechanism
Marshall explains atacicept's mechanism targeting BAFF and APRIL and its rationale for treating IgA nephropathy.
Play episode from 01:26
Transcript
